Skip to content

A multicenter registration study comparing aspiration embolization and stent embolization in acute anterior circulation intracranial large vessel occlusion stroke with large core infarction

A multicenter registration study comparing aspiration embolization and stent embolization in acute anterior circulation intracranial large vessel occlusion stroke with large core infarction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044979
Enrollment
Unknown
Registered
2021-04-03
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Aspiration recanalization treatment group:First choice of aspiration recanalization
Stent thrombectomy group:First choice of retrievable stent

Sponsors

The Second Affiliated Hospital of the Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. 18 years of age or older; 2. Diagnosed as anterior circulation ischemic stroke based on clinical symptoms or imaging examination; 3. CTA/MRA/DSA confirmed as internal carotid artery intracranial segment, middle cerebral artery M1 or M2 occlusion ; 4. ASPECTS score <6; 5. The time from onset to treatment is within 24 hours.

Exclusion criteria

Exclusion criteria: 1. Cerebral hemorrhage; 2. Tenecteplase is contraindicated for intravenous thrombolysis; 3. Past mRS score >= 2; 4. Pregnant women and lactating women; 5. Allergy to contrast agents and nickel-titanium alloys; 6. Arterial tortuosity or other arterial diseases prevent the treatment device from reaching the target blood vessel; 7. With previous neurological or mental illnesses that hinder the evaluation of neurological function; 8. There are multiple vascular occlusions; 9. CT or MRI suggests that there is Space-occupying brain tumors (except for small meningiomas); 10. CT or MRI indicates cerebrovascular inflammation; 11. CTA or MRA or DSA indicates intracranial arteriovenous malformation or aneurysm; 12. With any late disease, life expectancy is not more than 6 months; 13. Patiennts who have difficulty completing the 90-day follow-up.

Design outcomes

Primary

MeasureTime frame
modified Rankin scale score at 90 days;

Secondary

MeasureTime frame
90-day modified mRS score 0-3 percentage;incidence of symptomatic intracranial hemorrhage within 48 hours;NIHSS score changed at 24h after treatment;timely successful recanalization rate;improvement in NIHSS between baseline and 24 hours, and 5~7d;mortality within 90 days;

Countries

China

Contacts

Public ContactYang Qingwu

The Second Affiliated Hospital of the Army Medical University

yangqwmlys@163.com+86 13657638868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026